Podcasts about blood cancer

A New Zealand blood cancer patient who was forced to leave his children behind and make a last chance dash to Australia to access funded drugs has now been given a cutting edge transplant that is not publicly available here. Tawhai Reti, who has myeloma, had exhausted all treatment options in NZ. Earlier this year he moved to Australia without his family to access the lifesaving drug Daratumamab, which isn't funded here. It worked so well he has now been given CAR-T cell therapy, which could put him into remission indefinitely. Tawhai and Lani Reti spoke to Lisa Owen.

Right Thinking with Steve Coplon | Guests: Richard KayThis week's show is called "With a Little Help from My Friends - Richard Kay. Tune in and hear Steve continue the countdown to his 500th show with guest Richard Kay. After interviewing Steve on his own international talk radio show, Richard said these words to Steve, “You've got to have your own show. I am going to find a network that will give you airtime.” That's how Right Thinking with Steve Coplon got its start nearly 500 shows ago. Through his own podcast, Reflections on the Word with Richard Kay, Richard teaches the Word of the Lord with the deepest understanding, sharing his wisdom in a way that can only come from a man who possesses profound knowledge bestowed upon him directly from the Lord. You will love listening to Richard and know why Steve treasures his friendship so very much.In this episode we continue the countdown to our 500th show and speak with Richard Kay, a longtime friend whose support helped start the program. We reflect on how we met, our shared backgrounds in faith, ministry, teaching, and public speaking, and Richard's contribution to our book on character and integrity.We also discuss obedience to the Lord, including seeking God's direction, trusting Him, and accepting sacrifice when we do not know the outcome. Richard explains his podcast series "Reflections on the Word", including his teaching on spiritual warfare, deception, the fall of man, and Jesus' victory over sin.We close by talking about faith, service, and discipleship, with emphasis on prayer, teaching, encouragement, and the value of friendship and family in our walk with the Lord.https://www.talknetworkradio.com/hosts/right-thinking

On Saturday night, folks will gather at the Sagamore Pendry to celebrate the Visionary of The Year for Blood Cancer United, which you might know was the Leukemia and Lymphoma Society. Former MLB outfielder and Towson alum Casper Wells is pitching in and batting cleanup in trying to raise funds and awareness and visits with Nestor here for some current Orioles chatter and ways you can help cancer patients. The post Former MLBer Casper Wells returns to talk blood cancer and Orioles finding bats and more runs first appeared on Baltimore Positive WNST.

Right Thinking with Steve Coplon | Guests: Lefford FateThis week's show is called "With a Little Help from My Friends - Lefford Fate" with Lefford Fate. Tune in and hear Steve continue the countdown to his 500th show with guest Lefford Fate. Every time Steve welcomes Lefford as a guest on his show, Steve is greatly honored. Lefford holds the distinct title of being the guest on Right Thinking with Steve Coplon more times than anyone else. Today Steve is honored even more than ever before by Lefford's presence, because today is Memorial Day and Steve has a chance to thank Lefford in person for his service to our great country – nearly 31 years.  Lefford is a man with the Heart of a Servant and lives by the core values of the United States Air Force: "Integrity first, Service before self, Excellence in all we do." Steve's life has been enriched by his beautiful friendship with Lefford. Your life will be enriched by listening to this show.In this episode, we continue the countdown to the 500th show with a focus on Memorial Day, service, and a long friendship between Steve and Leffert. We reflect on Leffert's military service, the values of integrity and service before self, and the importance of honoring those who gave all.We also look back at how the show began, its connection to the Napoleon Hill Foundation and Don Green, and how these relationships led to new introductions and prison outreach. We discuss service as a calling through corrections work, mentoring people leaving prison, and using the show to help others, and we close with themes of faith, character, and purpose. https://www.talknetworkradio.com/hosts/right-thinking

In this episode, we talk with Christy Donovan, DNP, RN, a Blood Cancer Coordinator at the the Blood and Marrow Transplant/ Leukemia Program at Northside Hospital Cancer Institute, about what survivorship really looks like after a stem cell transplant. The central message is that survivorship is not a finish line. It is a transition into a new normal. Many patients expect life to return to the way it was before diagnosis or transplant, but recovery usually feels slower, messier, and more emotional than that. Fatigue, side effects, fear, and frustration can last for months, and that does not mean something is wrong. It means recovery is still happening. We also focus on how important it is to set realistic expectations. Christy explains that early struggles do not define long term outcomes. A setback in the first weeks or months after transplant does not mean a patient will not go on to live a full and meaningful life. Recovery takes patience. Small wins matter. Walking to the mailbox, cooking a meal, or getting through a day with a little more energy can be major milestones. Over time, those moments add up. Another major theme is emotional recovery. We talk about the fear of recurrence and the challenge of learning what is normal after treatment versus what should be reported to a doctor. That education helps people feel more confident and less trapped by fear. We also touch on how easy it is to forget that some aches and pains may simply come with getting older, not always with cancer. That perspective can be grounding. Other survivors can be a valuable information resource, too. Support comes up again and again throughout the conversation. Caregivers remain important in survivorship, but their role changes. Friends, peer support, support groups, podcasts, and survivorship communities all help patients feel less isolated. Christy emphasizes the value of honesty and vulnerability, especially in telling people what kind of support is needed on a given day. Some days call for celebration. Some days call for rest. We also talk about the tension between wanting to get back to life and needing to stay safe. Many survivors ask when they can return to work, travel, attend church, or see family. That desire is a good sign. It shows hope. At the same time, it takes guidance from the healthcare team to know when and how to widen that protective bubble. The episode ends on a hopeful note. Christy shares that she does not think of one survivor story. She thinks of many faces. She describes the joy of seeing patients return months later looking stronger, brighter, and more like themselves. That image captures the heart of the episode. Survivorship is hard, but it is also full of possibility, growth, connection, and life after transplant. More: Northside Hospital Cancer Institute Blood & Marrow Transplant Program — https://www.northside.com/services/cancer-institute/cancer-treatment-options/blood-marrow-transplant-program Northside Hospital Cancer Institute Blood Cancer Program — https://www.northside.com/services/cancer-institute/cancer-programs/blood-cancer-program National Bone Marrow Transplant Link (nbmtLINK) — https://www.nbmtlink.org/ Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Introduction (00:40) Meet Christy Donovan (01:42) Survivorship as a transition (03:00) The role of caregivers and support after transplant (03:38) Early struggles vs long term outcomes (05:41) Emotional impact and fear of recurrence (07:02) Learning what is normal and what is not (07:55) Support groups, healing arts, and community (08:44) Being honest with friends about what you need (09:34) Managing energy and celebrating small wins (11:02) Patience, hope, and finding your people (13:15) Common questions in early survivorship (14:27) Expanding the protective bubble (15:20) The many faces of survivorship (17:03) Final encouragement and close National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Right Thinking with Steve Coplon | Guests: Psalmist ChadThis week's show is called "With a Little Help from My Friends" with Psalmist Chad. Tune in and hear Steve continue the countdown to his 500th show with guest Chad Forschino. It is a joy for Steve to share with you his friend, whom he declares, with no reservations whatsoever, to be the most all-in for the Lord person that he has ever met. There is absolutely no wavering with Psalmist Chad in his steadfast faith to Jesus. When you fix your eyes entirely on Jesus as Psalmist Chad does, you will be able to stand firm when faced with life's adversities and hardships. This show will change your life and bring you a deep sense of peace if you open your heart to receive this powerful message from Psalmist Chad and Steve.In this episode, we continue the countdown to the 500th show and speak with Psalmist Chad Forshino about his music and the story behind the name “Psalmist Chad.” He shares how many of his songs came from difficult seasons, where he brought his struggles to God and received melodies and lyrics in return as a kind of heart cry.We also talk about grace, suffering, and what it means to be with God in the wilderness. Chad reflects on the prodigal son, on belonging to God, and on trusting Jesus through adversity and in every situation. https://www.talknetworkradio.com/hosts/right-thinking

Christian, Satveer, and Ceinwen join Tatum to share their varied experiences of being diagnosed with a high-grade blood cancer. Christian had just moved out of home for the first time, Satveer was recently married and Ceinwen had given birth to her daughter, when they were thrust into the whirlwind of diagnosis and facing the impact of treatment.  They touch on how their diagnosis impacted family dynamics, feelings of isolation and the task of explaining the diagnosis to others. There are tips for what they wish they'd know about sooner (shoutout to cooling towels!) and why talking to others who get it, makes a big difference.  

Right Thinking with Steve Coplon | Guests: Bud ClarkeThis week's show is called "With a Little Help from My Friends" with Bud Clarke. Tune in and hear Steve continue the countdown to his 500th show with guest Bud Clarke. What a blessing for Steve to have Bud be his guest today. Bud is Steve's longest continuous, close friendship in his life. After listening to this show, you will understand how wonderful and how important it is to have lifelong close friendships. Remember that to have a friend, you must be a friend. https://www.talknetworkradio.com/hosts/right-thinking

Would like like to share feedback on this podcast? Or suggest another topic for us to explore? Click here, or email us at DocTalk@medstar.netOn this DocTalk episode, we chat with Dr. Joseph Roswarski, the lymphoma/leukemia attending at MedStar Georgetown University Hospital and the Georgetown Lombardi Comprehensive Cancer Center. Dr. Roswarski's medical career includes clinical care and research in hematologic malignancies, particularly lymphoma and multiple myeloma. For an interview with Dr. Joseph Roswarski, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net. Learn more about Dr. Roswarski.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

This week's show is called "With a Little Help from My Friends" with Jeff Heiser. Tune in and hear Steve begin the countdown to his 500th show with an encore edition of Steve's very first show with special guest, Jeff Heiser, the international radio personality, who gave Steve his start in radio on Success An Intentional Lifestyle! Nothing Happens Without You Taking The First Step. Jeff shares valuable tips on this show with Steve, such as “People don't care what you know until they know that you care.” His wisdom has been invaluable to the success of Right Thinking with Steve Coplon. You don't want to miss this show!  https://www.talknetworkradio.com/hosts/right-thinking

Community DC Host Dennis Glasgow welcomes back to the program, Ria Freydberg Marcario, the Executive Director for Blood Cancer United, formally know as the Leukemia & Lymphoma Society. Over the next 30 mins, topics include: the re-brand, mission & vision, what they do, research, advocation, events, donations volunteering and much more! See omnystudio.com/listener for privacy information.

Right Thinking with Steve Coplon | Guests: Nathan JenkinsThis week's show is called "Advancing My Purpose" with guest Nathan Jenkins. Tune in to hear Steve and Nathan have an engaging conversation about how making the decision to live a life of purpose and to be an encouragement to others can help those who need to move out of dark places and come into the light. This show will motivate you to move toward your own purpose. https://www.talknetworkradio.com/hosts/right-thinking

New Zealand's lack of investment in blood cancer drugs and treatments is forcing patients to seek care in countries like Australia and ChinaThe Oz/NZ great divide when it comes to treating blood cancerFind The Detail on Newsroom or RNZGo to this episode on rnz.co.nz for more details

Right Thinking with Steve Coplon.This week's show is called " Finish What You Start". Tune in and hear Steve talk about the importance of finishing what you begin. You will never get to where you want to go if you let difficulties stop you. https://www.talknetworkradio.com/hosts/right-thinking

Living with a chronic blood cancer can bring uncertainty, questions and a need for support that lasts well beyond diagnosis. In this episode, Nelly shares her experience living with chronic myeloid leukemia (CML), offering an honest look at treatment, side effects and daily life (including raising her three sons.) Joined by hematologist Dr. Lynn Savoie, we explore chronic blood cancers like CML and chronic lymphocytic leukemia (CLL), including how they're diagnoses, treated and managed over time. Visit our website for more information on CLL and CML.Looking for support? Our team is here to help. Contact us today.

Annual deaths from blood cancer have increased almost 40 percent in the past two decades, according to a new report that paints a grim picture of how the disease is being managed in Aotearoa. The State of Blood Cancer said it's one of the fastest growing contributors to cancer mortality and treatment here is not keeping pace with comparable countries. About 27,000 people in New Zealand are living with blood cancer and 3000 are diagnosed each year. Blood Cancer New Zealand's head of advocacy Rosie Shaw spoke to Lisa Owen.

Right Thinking with Steve Coplon | Guests: Steve ForbesThis week's show is called "You Gotta Stay Between the Lines Everyday" with guest Steve Forbes, owner of Master's Touch Barber School of Excellence. Tune in and hear Steve talk with Steve Forbes, the inspiration behind Right Thinking Foundation. Experience the incredibly powerful story of how he went from running the streets, went into prison and then turned his life around and became the owner/operator of a hugely successful barber shop for over twenty years and started a barber school. He turned his life around, so can you! https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon | Guests: Robin CasarjianThis week's show is called "Forgiveness" with guest Robin Casarjian, Founder/Executive Director of the Lionheart Foundation and author of the critically acclaimed book "Forgiveness: A Bold Choice For A Peaceful Heart".  Tune in and hear why Steve calls Robin one of the most beautiful human beings that he knows as they talk about Forgiveness. https://www.talknetworkradio.com/hosts/right-thinking

•Who's Right Potluck - Anthony Didn't Cook Anything •Roach, Man, Got An Emulsified Tattoo •Agreeing Is Very Not Fun •George W Bush's National Shirt Height Requirement •Banned From The School Board For Horniness •The Kids In Illinois Are Different Than The Kids In Chicago •They Changed Math And Made It New •Old Math = A Chalkboard + Chalk + A Lady •You Can Go Kinda Rogue… Just Not Cameras In Locker Rooms Rogue •Knock Knock. Who's There? Blood Cancer. •Hair Flu Medicine Works Really Well •Walmart Is Now Hiring Nipple Lookers •Pregnancy Officially Named Disability …And Much More!   Support Us on Patreon Get access to bonus episodes every week, ad free episodes, and join us on our weekly after show chats. https://www.patreon.com/WhosRight Watch us Live Tuesday (Bonus Episodes) and Wednesday on Youtube https://www.youtube.com/c/WhosRightPodcast Our website - https://whosrightpodcast.com/ For superchat sounds, send them over to Doug at doug.whosrightpodcast@gmail.com with "superchat" in the subject line Submit Dear Flabby Questions - https://whosrightpodcast.com/dearflabby/ Don't miss any updates or content. Find all our social media links located in our Linktree: http://linktr.ee/whosrightpodcast Link to our Discord - https://discord.gg/5jkc6NfAW8 Doug's Substack - https://mindofdorg.substack.com/ Deputy Butterbean's Playlist - https://open.spotify.com/playlist/4BgFV8Gik4pDL4HNiygudW?si=VUiKTlOIRuO7-JtZ5pjJ1Q&pi=0uChhaL3Stq-0 The infamous Beastie Boys episode - https://beastieboysepisode.com/ Fat Back Daddies on YouTube - www.youtube.com/@fatbackdaddies

Dr. Jim Berenson, Founder of the Institute for Myeloma & Bone Cancer Research and the Berenson Cancer Center, describes the Institute's work, which includes maintaining a large biobank of patient samples that support both its own research and that being conducted by external groups. This biobank is being used to develop new blood markers for faster disease diagnosis, to assess treatment efficacy, and to support drug development for multiple myeloma and other cancers. Real-time monitoring of patient symptoms with a mobile app is capturing critical, often-missed patient data and providing evidence of clinical trial success. Jim explains, "Myeloma is a bone marrow-based cancer of a type of white cell called a plasma cell. These cells normally make a type of protein antibody that helps us fend off infections. And what happens in myeloma is that one of these types of cells goes rogue and takes over the bone marrow.  As a result, these patients make lots and lots of only one type of antibody, and that protein becomes our tumor marker. They can get into trouble with their kidneys, their blood counts, their bones, and their immune system because they can become very compromised both by the disease and the treatment. Therefore, patients can develop frequent infections." "It's diagnosed mainly through blood work, bone marrow examination, and radiologic tests. The latter used to be X-rays, but today it is MRI, CT, or PET scans. The bone marrow test usually demonstrates too many plasma cells that are clonal, meaning they are all of one type. So, usually, the bone marrow plasma cells make up only one-half percent. Myeloma patients have no less than 10% and up to 99% plasma cells, and they are all of one type. They all make one antibody because normally one plasma cell makes one antibody, but this is a clone that's grown a lot in the bone marrow. So, because the bone marrow directly releases proteins into the blood, there's a lot of the myeloma cell-produced antibody in the blood and/or the urine of these patients." "We now have nearly 60,000 bone marrow and blood specimens collected over the last 25 years from our patients, and we collect them in a way that's very systematic. So we obtain blood weekly in the first month, and bone marrow when they undergo the procedure. And then after the first month, the blood is drawn and obtained for research and for the Biobank about every month. And this is a huge resource for not only our own research, which has uncovered two new blood biomarkers through the use of these samples. And we are also able to use the Biobank as a resource for other research groups and companies, whether biotech, pharma, or in vitro diagnostics, to see if they can find a new marker. So we send them a sample, and they can use it for their work." #IMBCR #MultipleMyeloma #HematologyOncology #PrecisionMedicine #PatientMonitoring #DigitalHealth #CancerResearch #Biomarkers #PersonalizedTreatment #QualityOfLife #MedicalInnovation IMBCR.org Download the transcript here

Dr. Jim Berenson, Founder of the Institute for Myeloma & Bone Cancer Research and the Berenson Cancer Center, describes the Institute's work, which includes maintaining a large biobank of patient samples that support both its own research and that being conducted by external groups. This biobank is being used to develop new blood markers for faster disease diagnosis, to assess treatment efficacy, and to support drug development for multiple myeloma and other cancers. Real-time monitoring of patient symptoms with a mobile app is capturing critical, often-missed patient data and providing evidence of clinical trial success. Jim explains, "Myeloma is a bone marrow-based cancer of a type of white cell called a plasma cell. These cells normally make a type of protein antibody that helps us fend off infections. And what happens in myeloma is that one of these types of cells goes rogue and takes over the bone marrow.  As a result, these patients make lots and lots of only one type of antibody, and that protein becomes our tumor marker. They can get into trouble with their kidneys, their blood counts, their bones, and their immune system because they can become very compromised both by the disease and the treatment. Therefore, patients can develop frequent infections." "It's diagnosed mainly through blood work, bone marrow examination, and radiologic tests. The latter used to be X-rays, but today it is MRI, CT, or PET scans. The bone marrow test usually demonstrates too many plasma cells that are clonal, meaning they are all of one type. So, usually, the bone marrow plasma cells make up only one-half percent. Myeloma patients have no less than 10% and up to 99% plasma cells, and they are all of one type. They all make one antibody because normally one plasma cell makes one antibody, but this is a clone that's grown a lot in the bone marrow. So, because the bone marrow directly releases proteins into the blood, there's a lot of the myeloma cell-produced antibody in the blood and/or the urine of these patients." "We now have nearly 60,000 bone marrow and blood specimens collected over the last 25 years from our patients, and we collect them in a way that's very systematic. So we obtain blood weekly in the first month, and bone marrow when they undergo the procedure. And then after the first month, the blood is drawn and obtained for research and for the Biobank about every month. And this is a huge resource for not only our own research, which has uncovered two new blood biomarkers through the use of these samples. And we are also able to use the Biobank as a resource for other research groups and companies, whether biotech, pharma, or in vitro diagnostics, to see if they can find a new marker. So we send them a sample, and they can use it for their work." #IMBCR #MultipleMyeloma #HematologyOncology #PrecisionMedicine #PatientMonitoring #DigitalHealth #CancerResearch #Biomarkers #PersonalizedTreatment #QualityOfLife #MedicalInnovation IMBCR.org Listen to the podcast here

Right Thinking with Steve Coplon.This week's show is called "Oh, What a Blessing!"  Tune in to hear Steve reflect on what a blessing his life is as he shares two letters from inmates he had the privilege of meeting along the way. It is really amazing how when you are working for the Lord, your life is so very beautiful! https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon.This week's show is called "The Light at the End of the Tunnel." Tune in and hear Steve share thoughts on a recent road trip that has provided clarity and confirmation that the path he is traveling through life is the right path.  This show will give hope and encouragement to all who listen. https://www.talknetworkradio.com/hosts/right-thinking

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing personalized, accessible information to help patients have more meaningful discussions with their healthcare providers, not to replace the clinician's role. Jen explains, "We know that tens of millions of people are using AI tools in general, like ChatGPT, for health questions, including patients with blood cancers like chronic lymphocytic leukemia or CLL, they're all turning to the different AI tools that are out there. And from our perspective, we see this continuous growth of use, we want to make sure that the right healthcare information is getting fed into those AI resources and tools so that patients are getting the most accurate information possible."   Meg elaborates, "Many patients are using these AI tools to make sense of everything from their PET scans to their blood results, to some of the treatment language they receive in their clinician's or doctor's office. And one of the things that I heard recently from a cancer patient who had uploaded his scans and some test results into an AI platform. And he called me incredibly concerned. He was very concerned about his prognosis and the limited treatment options that he believed were available to him." "So when I pressed further, I found out that this AI platform was the only source of information that he had. So I became concerned when I recognized that the information he received was antiquated. So the treatment results and some of the information he was working from in this incredibly anxious and anxiety-provoking moment were 10 years old. And so in this case, antiquated information was as dangerous as inaccurate information. And both of these remain top concerns at the Lymphoma Research Foundation. And I think across our sector, as we see more and more patients using these tools and platforms to help educate them about their disease and their treatment options." #LymphomaResearchFoundation #LRF #BeOneMedicines #LymphomaAwareness #AIinHealthcare #PatientAdvocacy #BloodCancer #HealthcareInnovation #PatientEmpowerment #PrecisionMedicine #CLL #HealthTech #CancerCare lymphoma.org BeOneMedicines.com Download the transcript here

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing personalized, accessible information to help patients have more meaningful discussions with their healthcare providers, not to replace the clinician's role. Jen explains, "We know that tens of millions of people are using AI tools in general, like ChatGPT, for health questions, including patients with blood cancers like chronic lymphocytic leukemia or CLL, they're all turning to the different AI tools that are out there. And from our perspective, we see this continuous growth of use, we want to make sure that the right healthcare information is getting fed into those AI resources and tools so that patients are getting the most accurate information possible."   Meg elaborates, "Many patients are using these AI tools to make sense of everything from their PET scans to their blood results, to some of the treatment language they receive in their clinician's or doctor's office. And one of the things that I heard recently from a cancer patient who had uploaded his scans and some test results into an AI platform. And he called me incredibly concerned. He was very concerned about his prognosis and the limited treatment options that he believed were available to him." "So when I pressed further, I found out that this AI platform was the only source of information that he had. So I became concerned when I recognized that the information he received was antiquated. So the treatment results and some of the information he was working from in this incredibly anxious and anxiety-provoking moment were 10 years old. And so in this case, antiquated information was as dangerous as inaccurate information. And both of these remain top concerns at the Lymphoma Research Foundation. And I think across our sector, as we see more and more patients using these tools and platforms to help educate them about their disease and their treatment options." #LymphomaResearchFoundation #LRF #BeOneMedicines #LymphomaAwareness #AIinHealthcare #PatientAdvocacy #BloodCancer #HealthcareInnovation #PatientEmpowerment #PrecisionMedicine #CLL #HealthTech #CancerCare lymphoma.org BeOneMedicines.com Listen to the podcast here

Right Thinking with Steve Coplon | Guests: Don GreenTune in and hear Steve and Don continue their conversation on Napoleon Hill's Philosophy of Success. This week, they will talk about the Mastermind Group, one of Napoleon Hill's most powerful and foundational principles.  Don is the world's foremost expert on this valuable principle. It is one of both Steve and Don's personal favorites of Napoleon Hill's principles. After listening to this show, you will understand why and be ready to use it yourself to move yourself toward a lifetime of success. https://www.talknetworkradio.com/hosts/right-thinking

Analysis from Pew shows state reserve funds — often called rainy day funds — largely fell in 2025. That's the first time that happened since the Great Recession. It's down from a record high for state rainy day funds nationwide just the prior year. But Louisiana actually had a record-high rainy day balance in 2025, but we can't rest easy, as it still falls short of the national average. To learn more about what this means and how the state uses reserve funds, we're joined by Page Forrest, associate manager of the Fiscal 50 project at The Pew Charitable Trusts. This Friday, LSU's Reilly Center for Media and Public Affairs will present its 2026 John Breaux Symposium. The topic: “American Media at 250.”They will be exploring the influence the media has exerted over civic life in America over the past two and a half centuries, as the U.S. approaches its 250th birthday.Michael DiResto, director of the Reilly Center at LSU, tells us more about the upcoming event that highlights centuries of American political journalism.  Earlier this year, Mary Bird Perkins Cancer Center in Baton Rouge became the first hospital in the region to offer a certain type of cancer immunotherapy — referred to as CAR-T-Cell Therapy — on an outpatient basis for certain blood cancers.Dr. Andrew Dalovisio, director of the Myeloma Lymphoma and Cellular Therapy Program at Mary Bird Perkins, tells us more about this life-saving treatment.—Today's episode of Louisiana Considered was hosted by Adam Vos. Our managing producer is Alana Schreiber. We get production support from Garrett Pittman and our assistant producer, Aubry Procell.You can listen to Louisiana Considered Monday through Friday at noon and 7 p.m. It's available on Spotify, the NPR App and wherever you get your podcasts. Louisiana Considered wants to hear from you!Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.Louisiana Considered is made possible with support from our listeners. Thank you!

Right Thinking with Steve Coplon | Guests: Don GreenThis week's show is called "Stories About Napoleon Hill" with guest Don Green Executive Director/CEO of the Napoleon Hill Foundation. Tune in and hear Steve and Don, have a captivating conversation as Don shares stories, both personal and stories about Napoleon Hill,  author of Think and Grow Rich, one of the bestselling books of all time on the philosophy of personal achievement. https://www.talknetworkradio.com/hosts/right-thinking

The Health Minister has agreed to meet with a group of blood cancer specialists who wrote an open letter expressing their alarm at Kiwi patients dying unecessarily because Aotearoa is lagging behind with treatments. The dozens of doctors, nurses and clinician reseachers say New Zealand blood cancer patients are being deprived of modern, targetted, funded, go to treatments, that are available globally; including the myeloma drug, Daratumumab. Professor Judith Trotman is the Chair of the Australasian Leukaemia Lymphoma Research Group and an expat Kiwi-Australian haematolgist in Sydney she spoke to Lisa Owen.

When Megan Gilmour's son was 10 years old, he spent nearly two years in isolation at the Sydney Children's Hospital. The months he missed at school didn't just affect him academically. Megan, her daughter and her husband all relocated from Canberra to be with Darcy in Sydney as he underwent life-saving medical treatment, and lived at hospital.Over his many months in hospital, Darcy missed a lot of school. What worried Megan wasn't just that he was falling behind academically, it was his loneliness and the way he was losing connection to his friends and his community.Over time Megan watched how Darcy's sense of belonging vanished because he wasn't physically at school.So along with two other mums she met through the Sydney Children's Hospital, Megan decided to do something about it.Not just for the kids who are missing out of school because they are in hospital, but for the growing number of kids who are away from school for a whole host of reasons.Megan is the CEO and co-founder of Missing School, and she was the 2025 ACT Australian of the Year.This episode of Conversations was produced by Meggie Morris. Executive Producer is Nicola Harrison.It explores chronic illness, sick kids, school non attendance, school refusal, my kid doesn't want to go to school, young carers, neurodiverse children, autism, ADHD, AuDHD, learning difficulties, childhood cancer, blood disorders, lonely children, invisible siblings, parenting, motherhood, online learning, COVID, digital schooling, bone marrow transplant.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

A group of blood cancer specialists are expressing their alarm at the unnecessary loss of kiwi lives due to treatment in New Zealand lagging behind international standards. Dozens of doctors, nurses and clinician reseachers have written an open letter to the Prime Minister pleading for improvements in blood cancer care. They say New Zealanders are dying because they cant get drugs that are funded overseas and they're also being cut out of clinicial trials. Auckland haematologist Doctor Rory Bennett signed the letter spoke to Lisa Owen.

The plight of a New Zealand blood cancer patient forced to leave his four children behind and make a last chance dash to Australia for treatment has prompted dozens of doctors to write an open letter to the Prime Minister pleading for change. Tawhai Reti, who diagnosed with myeloma in 2019, exhausted all funded treatment options here and after being told he had weeks to live, was forced to most to Australia for funded treatment. His wife Lani Reti spoke to Lisa Owen.

Right Thinking with Steve Coplon | Guests: Don GreenThis week's show is called "Positive Influences." Tune in to hear Steve as he dedicates this show and the next two weeks to his good friend, Don Green, in honor of Don's 85th birthday, which was celebrated this past week. Steve shares some of the most important influences in his life leading up to Napoleon Hill, author of the masterpiece, Think and Grow Rich. This show will give you many valuable pointers, including the importance of surrounding yourself with the right people.https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon | Guests: Jim StovallThis week's show is called "A Message from Jim Stovall" with guest Jim Stovall. Tune in and hear Steve interview Jim Stovall, internationally acclaimed author, motivational speaker, and International Humanitarian of the Year.  This interview is the fourth in a four-part series featuring four of the most inspirational, motivational people that Steve has the privilege to call his friends. Listen to Jim share his story and be inspired as you have never been before. “You change your life when you change your mind" – Jim Stovall.https://www.talknetworkradio.com/hosts/right-thinking

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Carly Trulock-Quinn and I met through the Indy running community. Since I've been inspired by her, I know others will be too. During this episode, sponsored by Relay Active, Amazfit, and Cure, we talk about:The club she's part of - Fishers Running Club - Carly sits on the boardThe friends she's made through running that she now can't imagine life withoutFinding running through her parents and her grandfatherHow she decided to run in college Her high school injuries and being diagnosed with REDSMore about how the Fishers Running Club shows up for each otherThe Prairie on Fire backyard ultramarathon  Fitting running into her busy lifestyle Avoiding burnout from runningMental health: how running is running and therapy is therapyThe Tunnel Marathon she ran in Washington stateSponsor Details:Relay Active - Use MILESTONES for 15% offAmazfit - Use ALLYB for 10% offCure - Find a store near you or buy on AmazonPrevious Guests Mentioned:Sara FarneyAlan ErrichielloJon KuhnTJ DaileyMark GuyerOther Links:SUPPORT CARLY'S BLOOD CANCER UNITED CAMPAIGNIndy Mini Live Podcast Event TicketsJon Kuhn's films about Prairie on Fire and The Speed Project: The First Four, Chasing 100, and TSPThis is a SandyBoy Productions podcast.Follow me on Instagram.

In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.   Timestamps:   00:00 – Introduction  02:20 – What drew Anna to haematology  03:57 – Chronic lymphocytic leukaemia  08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia  12:19 – OxPLoreD and STELLAR aims  15:52 – Liquid biopsies  19:56 – Global diagnostics implementation challenges  25:57 – Integrating molecular testing clinically  29:20 – Training future precision leaders  33:51 – Next breakthroughs in precision haematology  35:35 – Three magic wishes 

Blood cancers are the fifth most common group of cancers in the UK. But for a small number of people, the condition may have an inherited genetic cause.  In this episode of Behind the Genes, we explore the role of genetics in blood cancer, and what an inherited risk means for patients and their families. Our guests explain what blood cancer is, how inherited factors can increase risk, and why multidisciplinary teamwork is key to supporting families. They also look ahead to future advances, from whole genome sequencing to prevention trials.  Our host Amanda Pichini, Clinical Director at Genomics England, is joined by:  Dr Katie Snape, Principal Clinician at Genomics England and Consultant Cancer Geneticist  Bev Speight, Principal Genetic Counsellor Dr Sarah Westbury, Consultant Haematologist “By doing whole genome sequencing we get all of the information about all of the changes that might have happened, we know whether any are inherited, but importantly, we're certain of the ones that have just occurred in the cancer cells and can help guide us with their treatment.”  You can download the transcript or read it below. Amanda: Hello, and welcome to Behind the Genes.  Sarah: When we think about blood cancers, it's a whole range of different conditions and when you talk to patients who are affected with blood cancers or are living with them, their experiences are often really different from one another, depending in part on what kind of blood cancer they have.  We also know that blood cancers affect not just the cell numbers but also the way that those cells function, and so the range of symptoms that people can get is really variable.  Amanda: I am your host, Amanda Pichini, clinical director at Genomics England and genetic counsellor.  Today I'll be joined by Dr Katie Snape, principal clinician at Genomics England and a consultant cancer geneticist in London, Bev Speight, a principal genetic counsellor in Cambridge, and Dr Sarah Westbury, and haematologist from Bristol.  They'll be talking about blood cancers and the inherited factors that increase blood cancer risk.  If you enjoy this episode, we'd love your support, so please subscribe, rate and share on your favourite podcast app.  Let's get started.  Thanks to everyone for joining us today on this podcast, we're delighted to have so many experts in the room to talk to us about blood cancer.  I'd love to start with each of you introducing yourself and telling us and the listeners a little bit about your role, so, Sarah, could we start with you?  Sarah: Sure.  It's great to be here.  My name's Sarah Westbury, and I'm a consultant haematologist who works down in Bristol.  And my interest in this area is I'm a diagnostic haematologist so I work in the laboratories here in the hospitals, helping to make a diagnosis of blood cancer for people who are affected with these conditions.  And I also look after patients in clinic who have different forms of blood cancer, but particularly looking after families who have an inherited predisposition to developing blood cancer.  And in the other half of my job, I work as a researcher at the University of Bristol.  And in that part of my job, I'm interested in understanding the genetic basis of how blood counts are controlled and some of the factors that lead to loss of control of those normal blood counts and how the bone marrow functions and works.  Amanda: Thank you.  That's really interesting, we'll be looking forward to hearing more about your experience.  Bev, we'll come to you next.  Bev: Thank you.  Hello everyone, I'm Bev Speight, I'm a genetic counsellor, and I work at Addenbrooke's Hospital in Cambridge.  I work with families with hereditary cancers in the clinical genetic service, and for the last six years or so have been focused on hereditary blood cancers.  So we've been helping our haematologists across the region to do genetic tests and interpret the results, and then in my clinic seeing some of the onward referrals that come to clinical genetics after a hereditary cause for blood cancer is found.  I'm also part of the Council for the UK Cancer Genetics Group.  Amanda: Thank you, Bev.  And Katie, over to you.  Katie: Hello, I'm Katie Snape.  I'm a genetics doctor and I am a specialist in inherited cancer.  So we look after anyone who might have an increased chance of developing cancer in their lifetime due to genetic factors.  I am the chair of the UK Cancer Genetics Group, so that's a national organisation to try and improve the quality of care and care pathways for people with inherited cancer risk in the UK.  And I have a special interest in inherited blood cancers through my work at King's College Hospital, I work in the haematology medicine service there seeing individuals who might have or have been diagnosed as having an inherited component to their blood cancers.  So it's great to be here.  Amanda: Excellent, thank you for those introductions.  I'd like to then dive right in and understand a little bit more about blood cancers.  So, Sarah, could you tell us a little bit more about what blood cancer is?  Sarah: Yes, sure.  The term blood cancer is used to describe a whole range of different kinds of cancer, all of which affect some part of the blood or sometimes parts of the immune system that kind of gets represented as part of the blood.  So it's really describing a big group of conditions rather than one single kind of condition or entity itself.  But like any form of cancer, we understand blood cancers as being conditions where because cells as part of the blood system are rapidly dividing and normally doing so under really well controlled circumstances to produce just the right balance of blood cells and just the right number of those cells.  In a cancer affecting those cells, we see that that loss of control results in either too many of one type of blood cell being produced or too few, or that balance being lost.  And like any form of cancer, this is because of genetic changes that happen in individual cells that then go on to grow in a way that is not controlled and well regulated.    And because when we talk about blood cancer we're talking about such a wide range of different kinds of cancer affecting different cells within that blood system, there's a really wide range of different conditions.  From conditions that we might think of as being like a form of acute leukaemia, so something that produces often symptoms and signs in patients very quickly and they can often feel quite unwell quite soon and then get picked up with having this condition because they present feeling unwell.  All the way to chronic and slow growing cancers that can be found completely by chance and serendipity when blood tests are done for other reasons.  So when we think about blood cancers, it's a whole range of different conditions.  And when you talk to patients who are affected with blood cancers or are living with them, their experiences are often really different from one another, depending in part on what kind of blood cancer they have.  We also know that blood cancers affect not just the cell numbers, but also the way that those cells function.  And so the range of symptoms that people can get is really variable, again depending on which of the blood cells are really affected by that.  And it may be that during the course of some of the conversations we have today in this podcast, we'll perhaps focus on particular kinds of blood cancer.  But like any cancer, it's that disruption of the normal growth and development of cells that means that the number and function of those blood cells has been disrupted in some way.  Amanda: Thank you so much for explaining that, Sarah, that's really helpful.  In terms of across the range of blood cancers, is that something that people can get at any age, and how common is it?  Sarah: It does depend, as we were sort of talking about that really wide range of different disorders that make up that group of blood cancers.  And individually each of those blood cancers is reasonably uncommon compared to cancers that we might typically think of, like breast cancer or colon cancer.  But actually, if you group blood cancers together, they make up quite a sizeable proportion, and they're actually as a group the fifth most common form of cancer that's diagnosed in people in the UK.  In adults in particular we think that perhaps people diagnosed with leukaemia would make up about 3% of the new diagnosis of cancer made in any year.  Amanda: So coming to you, Bev, when we talk about inherited blood cancers, what are the differences between those and blood cancers more generally?    Bev: So at point of diagnosis, it may not be obvious that somebody with a new blood cancer diagnosis is one of the minority of people in that big group as Sarah has described, who has an inherited cause.  So it may not be immediately obvious.  However, in the last few years certainly, it's become more and more routine to do quite broad genetic testing.  Often on a bone marrow sample or blood, because that is done looking for genetic changes, which are part of all cancer and we find within cancer cells, that can help with treatment planning.  It can also find that there is an inherited cause to that new blood cancer diagnosis.  Sometimes that might not be clear cut, sometimes that might be inferred from the genetic tests that are done on the blood or the bone marrow. And the proportion of blood cancers in that huge group which do have an inherited cause is fairly small, the actual proportion will depend a bit on the age of the patient and the specific subtype of blood cancer.  Amanda: Okay, and could you talk us through how some of those inherited genetic factors can increase the chance of a person developing blood cancer, how does that work?  Bev: Yes, so if we know that there is an inherited cause for blood cancer, then what we mean by that most of the time is that a change in a single gene has been found.  And that there is enough research evidence and enough known about that specific change in that gene to say to the person who's been diagnosed, there is at least in part or perhaps a full explanation for why that blood cancer has developed and this could be shared in the family.  So at that point it's information that not only has implications for the person in treatment, but also their relatives.  Depending on what sort of gene alteration it is and which gene it's found in, there are different inheritance patterns, and that changes the sorts of information that we give about risks for relatives.  So for lots of the genetic tests that detect an inherited cause in adults when they're diagnosed, that's most often what we would call an autosomal dominant inheritance pattern.  Essentially that means you only need to have one gene alteration which is in that person's normal non-cancerous DNA inherited from a parent and can be passed onto a child.  And for people in the family who have inherited this one genetic change, then they are likely to be at increased risk of developing blood cancer.  Sometimes with particularly the children's blood cancers, if an inherited cause is found, it can be a different pattern, which we call autosomal recessive.  And that's where two gene changes are found and one has been inherited from each parent.  So parents might be what we call carriers and have one each just by chance, both have been passed onto a child who has developed blood cancer either in childhood or possibly later on, and that's the pattern we call autosomal recessive.  There are other inheritance patterns too.  The third one that we come across being X-linked, and so that has a gender component.  That's where there's a change on the X chromosome, women have two X's, and men have one X and one Y.  So sometimes with the X-linked conditions we're more likely to see the clinical signs of a condition in boys and men because they've only got that one X chromosome.  But those are less common in the context of talking about hereditary blood cancers.  Amanda: Thank you.  That's really helpful to understand.  So it sounds like you're saying that these forms of blood cancers that are caused by a single gene are relatively rare.  And also by having one of these changes, it's not a given that that person will develop a blood cancer, but it makes them more likely, and how likely that is might depend on the inheritance pattern or the type of condition.  Bev: That's right.  So what we're saying is it can give either part of full explanation for the blood cancer diagnosis, and it could confer a risk to family members, but that doesn't mean they definitely will develop it.  We're talking about an increased risk compared to the population risk.  Amanda: Right.  I can imagine for those families to some extent it might be helpful to know the underlying reason why they had that blood cancer, but again, that's just a small proportion.  So, Katie, could I come to you next?  What about the rest of all the blood cancers, how do they occur?  Katie: Yes, thanks, Amanda.  So most blood cancers will occur just by chance.  We also know that there are some environmental factors that can increase the risk of blood cancers, so, for example, serious radiation exposure, something like that.  What Bev has described is where there is this sort of quite rare condition where there is a kind of single gene that's really important for the blood cells in terms of keeping those control mechanisms that Sarah described.  And that's not working properly, which has increased the risk of a blood cancer.  But we also sometimes see some families where there is more blood cancer, or the same type of blood cancer in that family than we might expect by chance.  We think that's probably not due to a single high risk genetic factor, but might be due to kind of multiple lower risk genetic factors that are sort of shared by close family members and can add up together to increase the risk a little bit.  And we call that familial risk or polygenic risk.  We don't have a test for that at the moment.  We wouldn't offer usually any extra screening or testing to those families, but we would just suggest obviously family members are aware of any signs of symptoms of blood cancers and seek any advice if they're concerned.  But, you know, the majority of blood cancers are not due to genetic factors, and it's sort of environmental or chance or bad luck. Amanda: Okay, so it's clear that obviously blood cancer is almost an oversimplification, within that category there's so many different types, so many ways that it could happen in a person.  So, Bev, if we're dealing with that type of blood cancer that is inherited or has some heritability, can you tell us more about what that means for the family?  What kind of impacts do you see that having for them?  Bev: Yes, of course.  So clearly this is another layer of information that's often coming at a family during a time where somebody is often recently diagnosed with blood cancer of one sort or another and is having to take in a lot of information about treatment and all of the uncertainty and anxiety that goes with that.  So for this minority of patients and families where there is new information about an inherited cause, that needs conveying in a timely but sensitive way, bearing in mind what else is happening.  And for some people it can come as a major shock and really an additional burden at that time.  I think the reaction to that will of course depend on lots of factors.  And what we also see is that this question about a new cancer diagnosis of any sort, including blood cancers, can generate the question in people's mind, particularly if they've got children, about does this change the risk for relatives?  So sometimes this new information that, actually, there is an inherited cause is an answer to a question that families have already got.  And that might be because of what Katie's described as familial clustering, there might already have been this known history in the family. So sometimes this information can feed into that and actually be quite a helpful answer.  But it's quite normal for families to feel quite mixed about this and for different family members to have a different approach to it.  When there's the offer of what we would call predictive testing, if we found a change in a single gene in somebody with blood cancer which we're saying is a hereditary cause for that, that might open the door for relatives to access predictive testing.  I.e., the opportunity to discuss and possibly take up a genetic test for themselves when they haven't had cancer themselves, but there's an opportunity to try and quantify whether or not they're at increased risk.  We know in families the uptake of those kinds of tests is different, and a lot of it is to do with timing and the way people respond to this in families might depend on their response to the cancer diagnosis in their relative, and of course what else is going on in their life at the time.  This aspect for the family is where clinical genetic services come in, because these initial tests in the person with blood cancer are done in their haematology/oncology setting, and normally the results about an inherited cause has been found are conveyed through that service.  That's when a referral to clinical genetics happens.  And in our specialist service we're addressing those additional concerns for the family which arise because of this diagnosis. Amanda: Thanks, Bev, for explaining that.  Sarah, coming back to you.  Could you tell me then if someone has an inherited blood cancer does it also change the way that the patient is treated? Sarah: Well, it certainly can do, and again, it does depend a little bit on the specific circumstances of that particular person and the form of inherited blood cancer predisposition that they have.  But certainly if we think about treatment as a whole, then for a lot of people it does affect the way that we might recommend treatments or look after them and their families.  So, for example, for some patients who have a diagnosis of an inherited form of blood cancer, we know that some treatments might be more or less effective for their particular set of circumstances.  And so that can sometimes influence the specific treatment recommendations that we would make, particularly thinking about, for example, the risks that the cancer might come back again after it's been treated.  Or thinking about whether or not some of the typical drug regimes that might be used might be perhaps more likely to cause them side effects or problems with tolerating that treatment.  So it can certainly make some changes in that respect. For some people, to be fair a minority of people with blood cancers, they may need a stem cell transplant as part of their treatment to hopefully cure them of their blood cancer.  And this as I say is a treatment that's required for a minority of patients as a whole who have a diagnosis of a blood cancer.  But for those people who have got an inherited predisposition and who might be recommended a stem cell transplant as part of their treatment, then knowing about a familial risk for this condition can also be really important.  For making sure that if a family member is being considered as a donor for example that we're being really careful to make sure that we're not choosing a donor that might also be affected by the same underlying blood cancer predisposition.  Because this can obviously cause problems for the person that's receiving the stem cells if it turns out that the person they're receiving them from actually has the same inherited condition as them.  So in that respect knowing about the underlying predisposition and genetic cause for their cancer can be helpful.  But in a more sort of general sense, yes, the other thing that it can have a big difference for is that some of these inherited cancer predispositions and syndromes also have other health conditions associated with them.  So it might be that that genetic diagnosis predisposes somebody not only to a form of blood cancer but to other health conditions as well.  And so actually knowing about that diagnosis can help their haematologist then make sure that they're linked in with the right other medical teams to make sure that those other health conditions are identified if they're present and taken care of.  And then I think really coming back to what Bev has already touched on, there's the sort of bigger picture of just how people are looked after in their own right but also as part of their family unit.  And making sure that they're given the right information and advice about their health, but also thinking about other family members.  And particularly for younger patients who perhaps either are just starting their own families or for whom that's not yet a consideration, making sure that they've got the information to understand what might be relevant for future family members, if that makes sense.  So it's not necessarily true to say that for every individual patient knowing that there's an inherited blood cancer present will necessarily directly affect the way that the treatment is offered.  But you can see that as a part of a bigger picture for a lot of patients, it will make a difference to their care as a whole.  Amanda: And you can really see how the impact is very sort of multigenerational and is going to affect people at all ages and stages of their life, so that's really interesting.  Katie, Bev spoke a little earlier about the fact that there are genetic tests that can help tell us if blood cancer is inherited.  Could you tell us more about what the tests involve, and some of your experience taking families through this?  Katie: There's sort of two main different ways that we might identify somebody has an inherited cause for their blood cancer through testing.  So traditionally what has happened, as Bev and Sarah sort of discussed before, is that when a person is diagnosed with a blood cancer, we either take a sample of their blood or bone marrow.  To try and look at what are the changes within those cells that have driven that cell to become a cancer cell and have driven this blood cancer to develop.  And a lot of the time, as we've said, it's not inherited, it's not genetic, so they're what we call acquired changes, they're changes that have just happened in the bone marrow or to the blood cells that have caused that kind of particular cell to become a cancer cell.  And it's really important that we look at those because that can help both diagnose the blood cancer, it can give us information about how serious that blood cancer might be, and it can also help us guide our treatments and therapies.  And so if we do those testings, they're primarily done within haematology for those sort of diagnostic or prognostic or treatment purposes.  We do sometimes see then a change that looks a bit suspicious that it might be inherited for various reason.  And if we see something that is in the cancer and it looks like there's a potential it could be inherited, we would go on and do a second test.  So usually because we can't do a blood test because the cancer's in the blood, we would take a skin biopsy.  And then we would look and see, well, is this change also present in the skin?  And if it is, then that indicates that that change is in all of the cells of the body, because it's in both the blood cancer and it's in the skin, and therefore it's likely to be inherited.  So that's one thing that we do.  And I think that that can be quite challenging for patients.  Because they go in to have a test for their blood cancer and then suddenly were being told, “Well, actually, we've also found something that might be inherited,” and it is something then that other members of the family might have.  And as Sarah said, potentially that means that even if your relative was offering to be a bone marrow donor for you, they might not be able to if they also carry the same thing.  And so that can be quite tricky just in terms of making sure that we're guiding the patient and their family members through that process.  And then thinking about the work that Genomics England does, particularly with whole genome sequencing, and this is particularly offered for children and young adults in the paediatric setting.  But I think we're also increasingly, as we progress we'll perhaps talk about this a bit, moving towards whole genome sequencing for adult blood cancers more routinely as well, that that is offered as a sort of standard of care.  And what whole genome sequencing is, is it is looking at the entire genetic instruction manual in both the blood cancer cells and in the cells that we're born with, to look at the inherited or germline genome as well.  And the reason that we look at both the cancer cells and the inherited or germline genome is because what we're trying to understand is firstly, are there any inherited changes that have led to the blood cancer developing?  But also, what are the changes that have just occurred in the cancer cells that are going to help us to diagnose and treat that blood cancer?  So by doing whole genome sequencing we get all of the information about all of the changes that might have happened, we know whether any are inherited, but importantly, we're certain of the ones that have just occurred in the cancer cells and can help guide us with their treatment.  And so, again, when we're talking to patients, we have to explain to them that we're going to be looking at their entire genetic information.  And what's interesting about that is it might find things that are not only relevant to blood cancer, but very rarely other findings, incidental findings as well, or we might find things that we don't know about.  But I think certainly that's something that patients often feel very comfortable with having because it gives them the maximum amount of information.  Amanda: Thanks, Katie.  So it really sounds like there's a lot of advancements that are being made in genetic technology which potentially brings a lot of new things for you and Bev as genetic specialists, but also for you, Sarah, as a haematology specialist.  What does that kind of change for you, and I assume it's really important then for you all to be working together as a multidisciplinary team?  Katie: Yes, I mean, I think for clinical genetics, we were not involved in sort of haematology pathways for a really long time, and the haematologists are absolute experts in the genomic factors that drive blood cancers.  And certainly in my practice, it's really only been as the technology advanced that we really started finding more and more of these inherited factors, particularly in the adult setting.  Because I think in the paediatric and childhood setting, the haematologists again have been managing those conditions very well for years.  And I think there's places that we really interface and we really need to work together as a multidisciplinary team, understanding the genetic information, really understanding when something that we've seen in the blood cancer or the bone marrow could be inherited.  Do we need to check that?  What should that pathway look like?  But I think as you've said, a lot of these are actually really quite new conditions, particularly in the adult setting.  And we don't yet 100% know why do some people get blood cancer and some people don't when they have the same inherited factor.  What's the actual risk?  Are there any other factors modifying it?  What makes some people progress to develop a blood cancer and some people not?  And for that we really need to work together to try and gather the data and sort of capture people that have these inherited changes.  And hopefully develop a system and an infrastructure that we can follow it long-term and get a lot of information about long-term outcomes, both for individuals with cancer but also their families.  And also from looking at doing population studies.  Because I think we know that lots of people in the general population might carry some of these inherited changes and never develop a blood cancer as a result of this, certainly ones that seem a bit lower risk.  So we really need to work together to understand all of that.  But I'd be really interested in Sarah's views on that as well.  Sarah: Yes, sure.  So I think, as you say, Katie, haematologists have got a long history of understanding and interpreting genetic findings in the sort of acquired or somatic changes that we know are what occurs in some blood cells to drive the cancer forming in the first place. But this kind of newer integration of that with the germline testing is something that is becoming much more mainstream in haematology now, and I think something that people have had to sort of acquire new skills in this area to interpret that alongside.  I think as you say, that multidisciplinary working, where we're able to benefit from both sides of our expertise and knowledge and put that together is so valuable, particularly in those circumstances where there is some uncertainty.  And I think as a haematologist, one of the things that I really find a benefit both personally and professionally to help me navigate these tricky questions but that I also think patients benefit from is your expertise and ability to have those really quite tricky conversations with people who are not haematology patients, if that makes sense.  So they may be the relatives of patients who have a haematological diagnosis for example.  Who at the moment are entirely well and were just going about their daily business, and they're now told that they may or may not potentially have this inherited predisposition.  And I think that as haematologists, we're very used to dealing with potentially quite poorly patients, potentially quite scared patients who find themselves, you know, the recipient of all this quite difficult information.  But we're not necessarily so skilled and experienced at holding conversations with people who don't yet have that diagnosis.  And I think that that's a really rich area of mutual aid to one another as haematologists and genetic doctors, if that makes sense.  And I think your points about understanding actually the real risks and the nature history, as we would call it, of what happens to people who carry these variants that predispose them to blood cancers is something that we can probably only work out by working together.  And of course, working with the patients and families that are affected by these conditions so that hopefully for both sides in the future we'll be able to give much better advice to patients and their families.  Amanda: So, Bev, from your experience and as a genetic counsellor, what do you feel are the important things that patients and their families should know as they're going through this testing and diagnosis process?  Bev: The things I think families where there is a hereditary cause found should know is that with this new information comes a whole new referral to a dedicated service.  Who want to help patients and their family members at risk to navigate this, to adjust the information, and to make decisions that fit with them, about whether to have testing and the timing of that.  As we already said, where there is a hereditary blood cancer risk, that risk in family members is rarely 100%.  Depending on what the hereditary predisposition is in the family, we may be able to quantify that risk, sometimes we can't always.  And the other thing to know which links to that is that there is growing interest in research in this area.  That will really help us to improve care in terms of, for example, being able to quantify the risk of developing a blood cancer in relatives who are perfectly well that may have inherited these predisposition gene changes.  Or, for example, the other obvious place where we want to make improvements in terms of some sort of evidence-based surveillance for those people who want to find out that they have inherited the genetic change and are at increased risk.  Amanda: Thank you.  And overall there's been a lot I think we've been covering today that's probably going to be very new to many people.  Why do you think it's important to raise public awareness of inherited blood cancers?  Bev: There have been lots of public awareness campaigns about other cancers, as listeners probably can think about, in terms of for women checking their breasts and breast cancer awareness.  And perhaps there's been a bit less of that in general for blood cancers.  As we've already talked about, clinical genetics were not so involved in all of the genetic testing happening in blood cancers.  Because it wasn't so long ago in the history of how we think about inherited cancers in general that our suspicion of inherited causes in leukaemia was much lower than it is now.  So I think that awareness in the public probably will take a bit more effort to bring up.  But clearly public awareness about blood cancers in general, symptom awareness, and the fact that occasionally it can be something that is running in the family, clearly better public awareness of that means that people are empowered to ask the right questions.  And the questions that might already be in some way going through their minds of their haematology doctors or perhaps of their GP, if they've got a family history but are not affected themselves.  Amanda: Wonderful.  So, looking now to the future, Katie, what genomic advancements are we seeing or are we likely to see that could impact on the care of people with an increased genetic risk of blood cancer?  Katie: We touched a little bit, I think that whole genome sequencing is expanding.  And as we can turn that test around and get it back more quickly that might become more commonplace.  And I know Genomics England and the UK Haemato-oncology Network of Excellence have been doing a lot of work in that area.  We are very lucky now we have a national inherited cancer predisposition register that NHS England have set up with the National Disease Registration Service.  So that will enable us to capture individuals that have these sort of rarer but single gene disorders or conditions that increase the chance of developing blood cancers.  And that will enable us to do that sort of longer-term follow-up and get really more information.  We've touched on this already but I think there's really amazing research happening, why do some people develop blood cancers and some people don't, even though everyone carries the same underlying change that increases the risk?  And then I think really importantly, we're seeing now in some conditions, clinical trials of certain medications to see if that can actually prevent people who carry these inherited changes from progressing to developing blood cancers.  So I think all of those things are really exciting and will give us lots more information that we can then help patients and their families, particularly the sort of treatment and trials aspects.  Amanda: And, Sarah, on treatment and trials, how do think genomics might improve the treatment, but also the diagnosis of people with inherited blood cancers in the future?  Sarah: I think, you know, hopefully when we are able to accrue more information about these underlying genetic predispositions and how they actually then affect people's likelihood of developing blood cancer, we'll be able to build on what we have so far to make that just feel much more robust and evidence based.  And it feels like at the moment there are many of us struggling to bring together small threads of evidence that have been accrued in the UK but in other centres around the world that are also interested in understanding this inherited blood cancer risk.  In such a way that we can actually give patients and their families more clear information and advice about what that means to them.  And I think that in terms of the diagnosis of blood cancer, I think this is something that Bev alluded to.  If we could better understand who might benefit for example from having regular screening or monitoring blood tests performed to see whether we can detect an emerging blood cancer.  Versus identifying those people who actually, the chances of them developing a blood cancer are so small that doing those tests is likely to do them more harm than good.  Perhaps by just causing them to be anxious or have other sort of unintended consequences of that kind of testing.  So understanding something more about that natural history, as we've already alluded to, will hopefully improve our ability to go from the diagnosis of the predisposition condition to working out how to then diagnose the blood cancer on the back of that.  And with time, I think as Katie has alluded to, thinking about more specific treatments and more tailored treatments to the individual predisposition condition and the blood cancer.  So whether it's that you're intervening before the blood cancer has developed to try and reduce that happening, or whether it's that you're then treating the blood cancer after it's developed.  Understanding the genetic basis and what it is that causes that transition would be really helpful and I think that is something that will come but will take time.  And I think on a sort of national level what I would really hope to see over time is that we're able to use that improvement in evidence base to then be able to bring together perhaps more defined patient pathways.  So that if you're diagnosed with a particular condition, one of these leukaemia predisposition syndromes or another form of blood cancer predisposition, there's a recognised strategy and set of steps that should be taken for all of those patients.  To make sure that they're getting equity of care and make sure that everything is being done in a way that feels safe, sensible and appropriate across the country.  While still then enabling us to give really personalised treatment to that individual person and what that diagnosis means for them.  But I think until we've gathered more information and more evidence we are just in the process of trying to do that to then bring about those changes.   Amanda: If you enjoyed today's episode, we'd love your support.  So please subscribe, share and rate us on wherever you listen to your podcasts.  I've been your host, Amanda Pichini.  This podcast was produced by Deanna Barac and edited by Bill Griffin at Ventoux Digital.  Thank you for listening. 

Right Thinking with Steve Coplon | Guests: Jim StovallThis week's show is called "Managing Expectations and Initiatives" with guest Jim Stovall. Tune in and hear Steve and Jim talk about how we control keeping our word by being more careful when we give our word.  Bestselling author, internationally renowned storyteller, Jim's wisdom has changed the lives of millions, and it will change your life too.https://www.talknetworkradio.com/hosts/right-thinking

The Health Minister won't say if the government has met its promise to blood cancer patients in New Zealand - that is that they have not been forgotten. Pharmac has proposed to fund two new combination medicines to treat a type of blood cancer - chronic lymphocytic leukaemia or CLL. The drugs can help those with CLL achieve longer lasting remission and avoid the need for traditional chemotherapy. Patients and advocates are celebrating, but Blood Cancer NZ and the Ministers acknowledge more work needs to be done. Lillian Hanly reports.

Right Thinking with Steve Coplon | Guests: Sonny EnglishThis week's show is called "The Message in the Music - Part 2" with guest Sonny English. Tune in and hear Steve and Sonny offer wisdom and encouragement to those of us needing to change our environment. After listening to this show, you will realize that there is much you can do to help your situation that you haven't been able to see before.https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon | Guests: Sonny EnglishThis week's show is called "The Message In The Music - Part 1 with guest Sonny English." Tune in and get inspired as you hear Steve and Sonny, a disabled army veteran, talk about staying positive through music. This show will warm your heart as you spend time with Sonny and experience what a beautiful person he is.https://www.talknetworkradio.com/hosts/right-thinking

ມູນນິທິ ມະເຮັງເລືອດຂາວ (The Leukemia Foundation) ເຕືອນວ່າ ເດັກນ້ອຍຫຼາຍກວ່າ 400ຄົນຕໍ່ປີ ອາດປະເຊີນກັບ ການກວດມະເຮັງເລືອດ (Blood cancer) ພາຍໃນສິບປີຂ້າງໜ້າ. ມູນນິທິ ກໍາລັງພະຍາຍາມຫາເງິນຈໍານວນ 12 ລ້ານໂດລາ ສໍາລັບການຄົ້ນຄວ້າ ແລະບໍຣິການຊ່ອຍເຫລືອ ຄອບຄົວທີ່ໄດ້ຮັບຜົນກະທົບ ຈາກໂຣກມະເລັງເລືອດ (Blood cancer) ຜ່ານໂຄງການ World's Greatest Shave, ດ້ວຍການຊຸກຍູ້ຜູ້ຄົນໃຫ້ແຖ, ຕັດ ຫລືຍ້ອມສີຜົມ ຂອງເຂົາເຈົ້າ ສໍາລັບ the World's Greatest Shave.

Send us a textIn this episode, Callie and Kraven sit down with two inspiring seniors, Jaeylynn Deutschman and Brennyn Treen, who are turning creativity into compassion. Through school fundraisers like Dimes for Donuts and the upcoming Winter Formal, they're rallying their classmates and community to raise money for Blood Cancer United - proving that small ideas can make a big impact. We talk about what motivated them to get involved, how student-led fundraising can spark real change, and what it feels like to leave a legacy of service in their final year of high school. It's a conversation about leadership, empathy, and the power of showing up for a cause bigger than yourself.For more information on their “Light the Fight” campaign, check out their link ⬇️ https://pages.lls.org/svoy/tol/svoynwoh26/KnightsLighttheFightThis episode was edited by Ace and sound recorded by Ollie S.Intro/Outro Music: “Motivated” by Alex MakesMusicDate Recorded: January 28th, 2026FOLLOW OUR SOCIALS:Twitter: @OHS_RoundTableInstagram: @ohs_roundtableEmail: podcast@otsegoknights.orgtiktok:  @ohs_roundtableStudent Video Show on YouTube: https://youtube.com/@lateknightsroundtablepodcast?feature=shared

Right Thinking with Steve Coplon.This week's show is called "Nine Years – A Message for the Ages." Tune in and hear Steve as he celebrates nine years of Right Thinking with Steve Coplon weekly shows and reflects on where he's been, who he is, and his new attitude about where he is now. This message gives a special thanks to Dr. Dennis Waitley and Jim Rohn, two of the most influential people in Steve's life who he has learned so very much from in his own personal development. This message will certainly bring you closer to finding your own purpose in life if you really listen.In this special episode titled "Nine Years, A Message for the Ages," I reflect on my transformative journey over nine years of hosting this podcast. I express my gratitude to influential figures such as Dr. Dennis Waitley and Jim Rohn for shaping my personal and spiritual growth. Sharing a poignant story from 1974, I describe my quest for adventure that led me to profound life lessons from a cowboy named Merle about love and connection. I also openly discuss recent health challenges, including my battle with cancer, and how they fostered resilience and a deeper perspective on life's seasons.Alongside significant literary influences, I emphasize the importance of nurturing connections and being present for one another, and of intentionally using our gifts to serve others. This episode serves as an inspiring call for listeners to embrace their unique paths with love and understanding.https://www.talknetworkradio.com/hosts/right-thinking

The Leukemia Foundation is warning more than 400 children a year could face a blood cancer diagnosis within the next decade. - Nagbabala ang Leukemia Foundation na mahigit 400 bata bawat taon ang maaaring ma-diagnose ng blood cancer sa loob ng susunod na dekada.

Right Thinking with Steve Coplon | Guests: Lefford Fate &  Henry SmithThis week's show is called "Toasting the Next Generation" with guests Lefford Fate and Henry Smith. Tune in and hear Steve welcome two of his favorite guests, Lefford Fate and Henry Smith. Lefford is a recipient of the Distinguished Toastmaster Award, the most prestigious award in Toastmasters International, signifying the highest level of educational and leadership excellence. Henry is one of the brightest lights of today's youth that Steve has the pleasure of knowing. Henry has recently joined Toastmasters, so it was a complete no-brainer for Steve to want to introduce Henry to Lefford. The timing is perfect for this meeting as Lefford will be launching his new book, Everybody Speaks, in the very near future. We are all going to become better speakers and communicators as we enjoy this powerful show.In this episode of "Right Thinking," I converse with Leffert Fate, a Toastmasters leader and author of "Everybody Speaks," and a young entrepreneur, Henry Smith. We discuss the impact of effective communication in leadership, personal expression, and the journey of finding one's voice.Leffert shares insights from his Toastmasters experience, while Henry reflects on overcoming public speaking nerves. We cover mentorship, practical speaking techniques, and the transformative power of community, reminding listeners that everyone has a story to share and urging them to communicate purposefully.https://www.talknetworkradio.com/hosts/right-thinking

Right Thinking with Steve Coplon.This week's show is called "Poco a Poco. Tune in and hear Steve celebrate the 250th episode of Right Thinking with Steve Coplon as he shares some reflections on how little by little one goes far.https://www.talknetworkradio.com/hosts/right-thinking

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 19 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Anthony Albanese - Australian Prime Minister Julie Inman Grant - Australia's ESafety Commissioner Dr Rachel Murrihy - Clinical Psychologist and Director of the KIdman Centre at Sydney's University of Technology Melanie Dawes - Chief Executive of Content Regulator Ofcom Lisa Nandy - UK's Culture Secretary Will Guyatt - The Smart 7's Tech Guru Reid Wiseman - NASA astronaut and member of Artemis crew Dr David Burtt - Postdoctoral Fellow at NASA's Goddard Space Flight CentreDr Mike Thorpe - Assistant Research Scientist at the University of Maryland, and the Planetary Environments Lab Division at NASADouglas Gonzaga de Sousa - Co-ordinator of the Centre for Specialty Coffees of Espirito SantoEdmond Rhys Jones - Co-lead at Boston Consulting Groups Centre for Climate and Sustainability Policy & RegulationBill Gates - Co-founder of Microsoft and high profile philanthropist Alyssa Tapley - Took part in the gene therapy trialProfessor Waseem Qasim - Consultant in Paediatric Immunology, and Professor of Cell and Gene Therapy at UCLDr Robert Chiesa - Consultant in Bone Marrow Transplantation at Great Ormond Street HospitalDr Roberto Biaggi - Co-author of the study from California's Loma Linda University.Celso Aguilar - Superintendent of the Toro Toro Park in BoliviaContact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk Presented by Ciara Revins, written by Liam Thompson, researched by Lucie Lewis and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

When doctors couldn't cure John Belfonte's blood cancer alone, family stepped in — and saved his life. Up next, the powerful story of how love, science, and one selfless act led to a cure.